Gain insights from TransMedics Group’s Q2 2025 earnings, highlighting 38% YoY revenue growth, raised full-year guidance, and innovation-driven future growth.

NetraMark Holdings Inc. (the 'Company” or 'NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation ( ...

The COA Research and Manufacturing Limited Company (COARMLC) has officially denied claims suggesting that its product, COA-72 ...

Kedrion Biopharma receives US FDA orphan drug designation for Coagadex to treat acquired Factor X deficiency: Fort Lee, New Jersey Thursday, July 31, 2025, 15:00 Hrs [IST] Kedrion ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

"While U.S. POINTER was designed and powered as a head-to-head comparison of the two interventions, and a statistically ...

The featured speaker will explore the potential benefits and technical and practical hurdles faced in real-world deployments through real-world examples. This session will also feature ive ...

In early-phase drug development, the success of a dose escalation study depends not only on the design but also on the speed and accuracy of decision-making across cohorts. Delays in progressing ...

Gain insights into Exelixis' Q2 2025 performance: 19% cabozantinib revenue growth, NET market leadership, and strategic advancements.

If included in National List of Essential Medicines (NLEM), the fixed-dose combinations (FDCs) to rein in hypertension can be ...

A clinical trial led by London Health Sciences Center Research Institute (LHSCRI) and Western University has found that a ...